Hoth Therapeutics Expands Clinical Trial Phase II in Europe to Treat Cancer-Related Skin Toxicities
Hoth Therapeutics Gains Momentum in Europe for Clinical Trials
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a pioneering biopharmaceutical firm focused on clinical innovations, has announced a significant advancement in its clinical trial program. The company will collaborate with ICON Clinical Research to broaden its Phase II clinical trial for HT-001, specifically focusing on cancer patients suffering from skin toxicities due to Epidermal Growth Factor Receptor Inhibitors (EGFRi). This initiative marks a pivotal step in the company’s growth strategy within the European market.
The Phase II trial, which is currently underway at various locations in the United States, aims to evaluate the efficacy, safety, and tolerability of topical HT-001. The drug is designed to alleviate the adverse skin effects experienced by patients undergoing treatment with EGFR inhibitors, a common therapeutic approach in oncology.
Expanding Horizons in Europe
According to Robb Knie, CEO of Hoth Therapeutics, the addition of clinical sites within the European Union (EU) is a crucial part of the company's international strategy.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.